Use of classic psychedelics may lower a person’s odds of developing opioid use disorder, said a new study published in the journal Scientific Reports.
COMPASS Pathways revealed positive topline results from the mental healthcare firm’s Phase IIB clinical trial on the use of COMP360 psilocybin to address treatment-resistant depression (TRD).
Biotech company Psycheceutical Inc. of Ft. Lauderdale, Fla., was issued two patents by the United States Patent and Trademark Office for what it calls a “precision duplicity” approach to delivering psychedelic drugs to patients.
Last year, LSD took a tentative, presumably groovy step back into the medical limelight when it was the featured performer in a controlled human trial for the first time in […]